AIM ImmunoTech Inc. (AIM) stock

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$0.15+0.00 (+0.13%)

Close on Nov 12, 2026Market cap $4.52MP/E –Yield –

AIM ImmunoTech statistics

71 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 11, 2026

Valuation ratiosIndustry

Market Cap: $4.52M; $289.51M
Enterprise Value: -$994.39K; $155.84M
PS Ratio: 49.64; 3.68
PB Ratio: 0.64; 2.13
P/TBV Ratio: 0.85; 2.38

Enterprise valuationIndustry

EV / Sales: -10.93; 2.65

Share statisticsIndustry

Shares Outstanding: 30M; 58M
Shares Change (YoY): 1254.9%; 10.9%
Shares Change (QoQ): 37.6%; 0.48%
Float: 27M; 49M
Shares Held by Insiders: 12.8%; 12.1%
Shares Held by Institutions: 3.77%; 56.4%

Short sellingIndustry

Short Interest: 1M; –
Short Interest Change: -7.21%; -0.80%
Short % of Float: 3.78%; 9.06%
Short % of Shares Outstanding: 3.29%; 6.30%
Days to Cover: 2.46; 5.15

Stock price statisticsIndustry

52-Week High: $1.88; –
52-Week Low: $0.12; –
20-Day Moving Average: $0.16; –
50-Day Moving Average: $0.18; –
200-Day Moving Average: $0.45; –
Average True Range (14): $0.01; –
Price Change (1 Week): -7.83%; -0.58%
Price Change (1 Month): -12.7%; -0.28%
Price Change (3 Months): -42.6%; -17.1%
Price Change (6 Months): -45.2%; -20.1%
Price Change (YTD): -86.9%; -20.1%
Price Change (1 Year): -90.6%; -19.3%
Price Change (3 Years): -99.7%; -22.2%
Price Change (5 Years): -99.9%; -76.4%
Price Change (10 Years): -100.0%; -62.4%
Average Volume (10 Days): 612,511; –
Average Volume (20 Days): 548,679; –
Average Volume (90 Days): 4M; –
Relative Volume: 0.20; 0.73
Relative Strength Index (14): 38.8; 47.7
Volatility (1 Year): 202.7%; 80.2%
Beta (5 Years): 0.83; 1.08

MarginsIndustry

Operating Margin: -12800.0%; -38.5%
Profit Margin: -15526.4%; -31.7%
EBITDA Margin: -12800.0%; -27.7%

Returns on capitalIndustry

Return on Equity (ROE): -2828.6%; -51.3%
Return on Assets (ROA): -185.4%; -40.7%
Return on Capital Employed (ROCE): -164.5%; -38.1%

Financial positionIndustry

Current Ratio: 2.75; 3.30
Quick Ratio: 2.60; 2.40
Debt / Equity: 0.20; 0.50
Interest Coverage: -14.27; -6.35

GrowthIndustry

Revenue Growth (YoY): -18.8%; 7.26%
Revenue Growth (3Y CAGR): -14.5%; 2.25%
Revenue Growth (5Y CAGR): -11.6%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.01; 0.40
WACC: 9.70%; 10.1%

Income statement (TTM)Industry

Revenue: $91.00K; $66.69M
Operating Income: -$11.65M; -$20.99M
Net Income: -$14.13M; -$21.61M
EBITDA: -$11.65M; -$16.85M

Balance sheetIndustry

Cash & Short-Term Investments: $6.95M; $66.80M
Total Debt: $1.44M; $116.91M
Net Cash (Debt): $5.51M; $16.56M
Net Cash Per Share: $0.18; $0.71
Equity (Book Value): $7.08M; $52.23M
Book Value Per Share: $0.23; $1.50
Tangible Book Value: $5.32M; $26.10M
Working Capital: $4.66M; $78.41M

Cash flow (TTM)Industry

Operating Cash Flow: -$12.23M; -$12.27M

Dividends and yieldsIndustry

Earnings Yield: -312.8%; -20.1%

Taxes and interestIndustry

Interest Expense: $816.00K; $2.98M

Scores and fair valueIndustry

Altman Z-Score: -67.06; 0.31
Piotroski F-Score: 3; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	AIM	S&P 500	Difference	AIM per year	S&P 500 per year
1 month	-16.2%	-2.7%	−13.5 pts
3 months	-42.2%	-1.7%	−40.4 pts
Year to date	-86.4%	+11.9%	−98.3 pts
1 year	-90.3%	+12.0%	−102.3 pts
3 years	-99.6%	+78.2%	−177.8 pts	-84.6%	+21.2%
5 years	-99.9%	+73.2%	−173.1 pts	-75.4%	+11.6%
10 years	-100.0%	+309.6%	−409.6 pts	-63.8%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

1M AIM shares were sold short on Oct 30, 2026, down 7.2% from the previous report, or 3.78% of the shares available to trade. At recent volumes it would take 2.5 days to buy them back. Over the last 20 sessions, 42.4% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	1,002,082	-7.2%	406,598	2.5
Oct 15, 2026	1,079,889	-23.3%	737,514	1.5
Sep 30, 2026	1,407,198	-49.1%	1,866,131	1.0
Sep 15, 2026	2,765,187	+382.9%	11,020,474	1.0
Aug 31, 2026	572,582	-17.2%	12,144,075	1.0
Aug 14, 2026	691,534	-24.3%	2,060,791	1.0
Jul 31, 2026	913,892	-40.8%	741,607	1.2
Jul 15, 2026	1,543,826	-29.9%	632,940	2.4
Jun 30, 2026	2,201,636	-31.3%	2,322,389	1.0
Jun 15, 2026	3,204,092	-54.3%	51,555,532	1.0
May 29, 2026	7,013,343	+5016.3%	123,199,850	1.0
May 15, 2026	137,078	-54.8%	1,558,811	1.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in AIM ImmunoTech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 12, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIM.

Compare: AIM vs INMB · AIM vs ABPO · AIM vs ARTV · AIM vs ATYR · AIM vs HIND

Company	Revenue	Growth
HIND	$153.10K	-55.6%
AIM	$91.00K	-18.8%
INMB	–	–
ABPO	–	–
ARTV	–	–
ATYR	–	–

Company

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Held by institutions: 3.8%
Auditor: BDO USA, P.C.
SEC CIK: 946644

Advertisement
300 × 250

See a number that looks wrong?